Back to Database
Follistatin 344
Follistatin-344
Also known as: FS-344
Moderate Risk
Muscle Growth
Antagonizes myostatin and activin, the body's natural limiters of muscle growth. Strong animal data but very limited human evidence for injectable form.
Benefits
Inhibits myostatin (muscle growth limiter)
Promotes muscle growth through multiple pathways
Durable muscle size/strength increases (animal data)
May counteract muscle wasting
Side Effects & Risks
Injection site reactionsmild
Limited human safety datamoderate
Potential reproductive effectsmoderate
Theoretical tendon/ligament strainmoderate
Dosing Information
Typical Dose
100-200 mcg, 2-3 times per week
Administration
Subcutaneous or intramuscular injection
Cycle Length
8-12 weeks
Notes
No formal human studies on SC peptide injection. Most evidence from gene therapy.
Legal Status
FDA Status
Not FDA-approved
Availability
Research peptide suppliers
WADA Status
Banned by WADA (athletes beware)
Evidence
Evidence LevelLow
Strong animal gene therapy data. NO formal human research on exogenous peptide injection. High gap between promise and evidence.